Astellas Pharma Company Insiders
| ALPMY Stock | USD 10.09 0.04 0.39% |
Astellas Pharma employs about 14.5 K people. The company is managed by 10 executives with a total tenure of roughly 15 years, averaging almost 1.0 years of service per executive, having 1452.2 employees per reported executive. Break down of Astellas Pharma's management performance can provide insight into the company performance.
| Yoshitsugu Shitaka President Executive Officer and Presidentident of Subsidiary |
Astellas |
Astellas Pharma Management Team Effectiveness
The company has return on total asset (ROA) of 0.0653 % which means that it generated a profit of $0.0653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0898 %, meaning that it generated $0.0898 on every $100 dollars invested by stockholders. Astellas Pharma's management efficiency ratios could be used to measure how well Astellas Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Astellas Pharma Workforce Comparison
Astellas Pharma is number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—General industry is presently estimated at about 318,667. Astellas Pharma holds roughly 14,522 in number of employees claiming about 5% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.09 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.17 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.17. Astellas Pharma Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Astellas Pharma Price Series Summation is a cross summation of Astellas Pharma price series and its benchmark/peer.
Astellas Pharma Notable Stakeholders
An Astellas Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Astellas Pharma often face trade-offs trying to please all of them. Astellas Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Astellas Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Yoshitsugu Shitaka | Executive Officer and Presidentident of Subsidiary | Profile | |
| Chihiro Yokota | Executive Officer, Director of Licensing and Alliance | Profile | |
| Minoru Kikuoka | CFO Officer | Profile | |
| Naoki BSc | Chief VP | Profile | |
| Kenji Yasukawa | Senior Executive Officer, Manager of Vaccine Business Promotion Office | Profile | |
| Stig Ogata | VP Communications | Profile | |
| Katsuyoshi Sugita | Chief Officer | Profile | |
| Nobue Yasuda | Gen Department | Profile | |
| Collette Taylor | VP HR | Profile | |
| Catherine Levitt | G Counsel | Profile |
About Astellas Pharma Management Performance
The success or failure of an entity such as Astellas Pharma often depends on how effective the management is. Astellas Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Astellas management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Astellas management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.
Please note, the imprecision that can be found in Astellas Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Astellas Pharma. Check Astellas Pharma's Beneish M Score to see the likelihood of Astellas Pharma's management manipulating its earnings.
Astellas Pharma Workforce Analysis
Traditionally, organizations such as Astellas Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Astellas Pharma within its industry.Astellas Pharma Manpower Efficiency
Return on Astellas Pharma Manpower
| Revenue Per Employee | 89.3M | |
| Revenue Per Executive | 129.6B | |
| Net Income Per Employee | 8.5M | |
| Net Income Per Executive | 12.4B | |
| Working Capital Per Employee | 33.8M | |
| Working Capital Per Executive | 49.1B |
Additional Tools for Astellas Pink Sheet Analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.